Gilead Judge Re-Opens Case Amid Claim Merck Scientist LiedBy
Witness is accused of deceiving jury about origins of patent
Merck was awarded $200 million in fight over hepatatis C cure
A federal judge re-opened Merck & Co.’s patent case against Gilead Sciences Inc. over a hepatitis C drug amid claims that an ex-Merck scientist lied to a jury that awarded the company $200 million in damages.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.